Wall Street brokerages expect Tilray Inc (NASDAQ:TLRY) to report sales of $17.32 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Tilray’s earnings, with the lowest sales estimate coming in at $12.24 million and the highest estimate coming in at $27.20 million. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 12th.
On average, analysts expect that Tilray will report full-year sales of $44.92 million for the current fiscal year, with estimates ranging from $39.84 million to $54.80 million. For the next financial year, analysts anticipate that the firm will report sales of $245.08 million, with estimates ranging from $141.99 million to $442.20 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Tilray.
Tilray (NASDAQ:TLRY) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.08). The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $10.25 million. Tilray had a negative net margin of 121.22% and a negative return on equity of 60.74%. The firm’s quarterly revenue was up 85.2% compared to the same quarter last year.
Shares of TLRY traded down $0.75 during trading hours on Wednesday, reaching $79.24. 1,802,204 shares of the company traded hands, compared to its average volume of 4,142,823. The company has a quick ratio of 4.98, a current ratio of 5.43 and a debt-to-equity ratio of 0.05. Tilray has a 1-year low of $20.10 and a 1-year high of $300.00.
In related news, insider Brendan Kennedy sold 149,916 shares of the stock in a transaction dated Thursday, January 24th. The shares were sold at an average price of $74.21, for a total value of $11,125,266.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CRO Edward Wood Pastorius, Jr. sold 29,422 shares of the stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $72.57, for a total transaction of $2,135,154.54. The disclosure for this sale can be found here. Insiders sold 199,916 shares of company stock valued at $14,787,514 in the last three months.
A number of large investors have recently bought and sold shares of TLRY. ETF Managers Group LLC bought a new stake in Tilray during the fourth quarter worth about $40,553,000. Morgan Stanley bought a new stake in Tilray during the third quarter worth about $27,240,000. DekaBank Deutsche Girozentrale bought a new stake in Tilray during the third quarter worth about $5,287,000. Artemis Investment Management LLP bought a new stake in Tilray during the third quarter worth about $6,519,000. Finally, Zimmer Partners LP bought a new stake in Tilray during the third quarter worth about $3,591,000. 6.10% of the stock is owned by hedge funds and other institutional investors.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Recommended Story: How analysts view the yield curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.